H.C. Wainwright analyst Douglas Tsao reiterates a Buy rating on Argenx (ARGX) with a $617 price target after the company said it is advancing efgartigimod subcutaneous in all three subtypes of ...

Spherix Global Insights highlights rising enthusiasm for Priovant’s TYK2/JAK1 inhibitor alongside continued dissatisfaction ...

SAN FRANCISCO--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic ...

Please provide your email address to receive an email when new articles are posted on . Among systemic rheumatic diseases, the risk for opportunistic infection is highest among patients with ...

PF1801 is a novel long-acting glucagon-like peptide-1 receptor agonist. The Food and Drug Administration (FDA) has granted Orphan Drug designation to PF1801 for the treatment of polymyositis.

Please provide your email address to receive an email when new articles are posted on . Among patients with myositis, younger individuals with dermatomyositis are more likely to experience pain, while ...

Idiopathic inflammatory myopathies, known collectively as myositis, are chronic diseases that cause disability, mainly from muscle weakness, despite the use of immunosuppressive therapies. An improved ...

In a new study from Karolinska Institutet, the researchers found that combining information from blood markers and genetics reveals distinct subgroups of patients with myositis, which may help to ...

The polymyositis market is witnessing notable growth driven by the increasing prevalence of this autoimmune disease, particularly among older adults. Polymyositis leads to muscle inflammation and ...

SAN FRANCISCO--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic ...